{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T10:48:50Z","timestamp":1789987730714,"version":"4.0.1"},"publisher-location":"Cham","reference-count":64,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783319914381","type":"print"},{"value":"9783319914398","type":"electronic"}],"license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018]]},"DOI":"10.1007\/978-3-319-91439-8_10","type":"book-chapter","created":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T20:25:48Z","timestamp":1533155148000},"page":"199-214","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Midostaurin: A Multiple Tyrosine Kinases Inhibitor in Acute Myeloid Leukemia and Systemic Mastocytosis"],"prefix":"10.1007","author":[{"given":"Richard F.","family":"Schlenk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Kayser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,2]]},"reference":[{"issue":"19","key":"10_CR1","first-page":"5353","volume":"52","author":"E Andrejauskas-Buchdunger","year":"1992","unstructured":"Andrejauskas-Buchdunger E, Regenass U (1992) Differential inhibition of the epidermal growth factor-, platelet-derived growth factor-, and protein kinase C-mediated signal transduction pathways by the staurosporine derivative CGP 41251. Cancer Res 52(19):5353\u20135358","journal-title":"Cancer Res"},{"issue":"15","key":"10_CR2","doi-asserted-by":"publisher","first-page":"4991","DOI":"10.1158\/1078-0432.CCR-04-0210","volume":"10","author":"P Bali","year":"2004","unstructured":"Bali P, George P, Cohen P et al (2004) Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3. Clin Cancer Res 10(15):4991\u20134997","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10_CR3","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1182\/blood-2014-12-614743","volume":"126","author":"S Barete","year":"2015","unstructured":"Barete S, Lortholary O, Damaj G et al (2015) Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis. Blood 126(8):1009\u20131016","journal-title":"Blood"},{"issue":"9","key":"10_CR4","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/bjc.1996.205","volume":"73","author":"J Budworth","year":"1996","unstructured":"Budworth J, Davies R, Malkhandi J, Gant TW, Ferry DR, Gescher A (1996) Comparison of staurosporine and four analogues: their effects on growth, rhodamine 123 retention and binding to P-glycoprotein in multidrug-resistant MCF-7\/Adr cells. Br J Cancer 73(9):1063\u20131068","journal-title":"Br J Cancer"},{"key":"10_CR5","doi-asserted-by":"crossref","unstructured":"Chu TF, Rupnick MA, Kerkela R et al (2007) Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet (9604);370:2011\u20132019","DOI":"10.1016\/S0140-6736(07)61865-0"},{"key":"10_CR6","doi-asserted-by":"publisher","first-page":"c6764","DOI":"10.1136\/bmj.c6764","volume":"341","author":"LC Claridge","year":"2010","unstructured":"Claridge LC, Eksteen B, Smith A et al (2010) Acute liver failure after administration of paracetamol at the maximum recommended daily dose in adults. BMJ 341:c6764","journal-title":"BMJ"},{"issue":"4","key":"10_CR7","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1111\/bjh.12916","volume":"166","author":"SS Cohen","year":"2014","unstructured":"Cohen SS, Skovbo S, Vestergaard H et al (2014) Epidemiology of systemic mastocytosis in Denmark. Br J Haematol 166(4):521\u2013528","journal-title":"Br J Haematol"},{"issue":"2","key":"10_CR8","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1365-2125.2010.03819.x","volume":"71","author":"DG Craig","year":"2011","unstructured":"Craig DG, Bates CM, Davidson JS et al (2011) Overdose pattern and outcome in paracetamol- induced acute severe hepatotoxicity. Br J Clin Pharmacol 71(2):273\u2013282","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"10_CR9","doi-asserted-by":"publisher","first-page":"3674","DOI":"10.1182\/blood-2006-02-005702","volume":"108","author":"DJ DeAngelo","year":"2006","unstructured":"DeAngelo DJ, Stone RM, Heaney ML et al (2006) Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high- risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. Blood 108(12):3674\u20133681","journal-title":"Blood"},{"issue":"3","key":"10_CR10","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/j.1365-2133.1995.tb08689.x","volume":"132","author":"E Delaporte","year":"1995","unstructured":"Delaporte E, Pi\u00e9rard E, Wolthers BG et al (1995) Interferon-alpha in combination with corticosteroids improves systemic mast cell disease. Br J Dermatol 132(3):479\u2013482","journal-title":"Br J Dermatol"},{"issue":"5","key":"10_CR11","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s00280-012-1825-y","volume":"69","author":"A Corral Del","year":"2012","unstructured":"Del Corral A, Dutreix C, Huntsman-Labed A et al (2012) Midostaurin does not prolong cardiac repolarization defined in a thorough electrocardiogram trial in healthy volunteers. Cancer Chemother Pharmacol 69(5):1255\u20131263","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"10_CR12","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1007\/s00280-013-2287-6","volume":"72","author":"C Dutreix","year":"2013","unstructured":"Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y (2013) Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers. Cancer Chemother Pharmacol 72(6):1223\u20131234","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"10_CR13","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1023\/B:DRUG.0000011790.31292.ef","volume":"22","author":"JP Eder Jr","year":"2004","unstructured":"Eder JP Jr, Garcia-Carbonero R, Clark JW et al (2004) A phase I trial of daily oral 4\u2019- N -benzoyl- staurosporine in combination with protracted continuous infusion 5-fluorouracil in patients with advanced solid malignancies. Invest New Drugs 22(2):139\u2013150","journal-title":"Invest New Drugs"},{"issue":"1","key":"10_CR14","first-page":"17","volume":"15","author":"D Fabbro","year":"2000","unstructured":"Fabbro D, Ruetz S, Bodis S et al (2000) PKC412-a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des 15(1):17\u201328","journal-title":"Anticancer Drug Des"},{"issue":"5","key":"10_CR15","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1038\/sj.leu.2404593","volume":"21","author":"Y Furukawa","year":"2007","unstructured":"Furukawa Y, Vu HA, Akutsu M et al (2007) Divergent cytotoxic effects of PKC412 in combination with conventional antileukemic agents in FLT3 mutation-positive versus -negative leukemia cell lines. Leukemia 21(5):1005\u20131014","journal-title":"Leukemia"},{"issue":"7","key":"10_CR16","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1182\/blood-2006-04-015545","volume":"108","author":"AC Garcia-Montero","year":"2006","unstructured":"Garcia-Montero AC, Jara-Acevedo M, Teodosio C et al (2006) KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 108(7):2366\u20132372","journal-title":"Blood"},{"issue":"10","key":"10_CR17","doi-asserted-by":"publisher","first-page":"3645","DOI":"10.1158\/0008-5472.CAN-04-0006","volume":"64","author":"P George","year":"2004","unstructured":"George P, Bali P, Cohen P et al (2004) Cotreatment with 17-allylaminodemethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3. Cancer Res 64(10):3645\u20133652","journal-title":"Cancer Res"},{"issue":"5","key":"10_CR18","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1182\/blood-2002-02-0492","volume":"100","author":"DG Gilliland","year":"2002","unstructured":"Gilliland DG, Griffin JD (2002) The roles of FLT3 in hematopoiesis and leukemia. Blood 100(5):1532\u20131542","journal-title":"Blood"},{"issue":"8","key":"10_CR19","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1182\/blood-2012-07-442400","volume":"121","author":"S Georgin-Lavialle","year":"2013","unstructured":"Georgin-Lavialle S, Lhermitte L, Dubreuil P, Chandesris MO, Hermine O, Damaj G (2013) Mast cell leukemia. Blood 121(8):1285\u20131295","journal-title":"Blood"},{"issue":"8","key":"10_CR20","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1182\/blood-2005-04-1568","volume":"106","author":"J Gotlib","year":"2005","unstructured":"Gotlib J, Berub\u00e9 C, Growney JD et al (2005) Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood 106(8):2865\u20132870","journal-title":"Blood"},{"issue":"26","key":"10_CR21","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","volume":"374","author":"J Gotlib","year":"2016","unstructured":"Gotlib J, Kluin-Nelemans HC, George TI et al (2016) Efficacy and safety of midostaurin in advanced systemic mastocytosis. N Engl J Med 374(26):2530\u20132541","journal-title":"N Engl J Med"},{"issue":"2","key":"10_CR22","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S1097-2765(03)00505-7","volume":"13","author":"J Griffith","year":"2004","unstructured":"Griffith J, Black J, Faerman C et al (2004) The structural basis for autoinhibition of FLT3 by the juxtamembrane domain. Mol Cell 13(2):169\u2013178","journal-title":"Mol Cell"},{"key":"10_CR01","doi-asserted-by":"crossref","unstructured":"Gu TL, Nardone J, Wang Y, et al (2011) Survey of activated FLT3 signaling in leukemia. PLoS One 6:e19169","DOI":"10.1371\/journal.pone.0019169"},{"issue":"6472","key":"10_CR23","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/368643a0","volume":"368","author":"C Hannum","year":"1994","unstructured":"Hannum C, Culpepper J, Campbell D et al (1994) Ligand for FLT3\/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs. Nature 368(6472):643\u2013648","journal-title":"Nature"},{"issue":"3","key":"10_CR24","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0145-2126(03)00259-5","volume":"28","author":"AW Hauswirth","year":"2004","unstructured":"Hauswirth AW, Simonitsch-Klupp I, Uffmann M et al (2004) Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature. Leuk Res 28(3):249\u2013257","journal-title":"Leuk Res"},{"issue":"5","key":"10_CR25","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/sj.onc.1203354","volume":"19","author":"F Hayakawa","year":"2000","unstructured":"Hayakawa F, Towatari M, Kiyoi H et al (2000) Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene 19(5):624\u2013631","journal-title":"Oncogene"},{"issue":"5","key":"10_CR26","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1124\/dmd.116.072744","volume":"45","author":"H He","year":"2017","unstructured":"He H, Tran P, Tedesco V et al (2017) Midostaurin, a novel protein kinase inhibitor for the treatment of acute myelogenous leukemia: insights from human absorption, metabolism, and excretion studies of a BDDCS II drug. Drug Metab Dispos 45(5):540\u2013555","journal-title":"Drug Metab Dispos"},{"key":"10_CR27","first-page":"54","volume-title":"WHO classification of tumors of hematopoietic and lymphoid tissues","author":"MP Horny","year":"2008","unstructured":"Horny MP, Metcalfe DD, Bennett JM (2008) Mastocytosis. In: Swerdlow SH, Campo E (eds) WHO classification of tumors of hematopoietic and lymphoid tissues. International Agency for Research and Cancer, Lyon, France, pp 54\u201363"},{"issue":"14","key":"10_CR28","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1056\/NEJMsm1605385","volume":"377","author":"MA Hern\u00e1n","year":"2017","unstructured":"Hern\u00e1n MA, Robins JM (2017) Per-protocol analyses of pragmatic trials. N Engl J Med 377(14):1391\u20131398","journal-title":"N Engl J Med"},{"issue":"11","key":"10_CR29","first-page":"1225","volume":"45","author":"Y Ikegami","year":"1995","unstructured":"Ikegami Y, Yano S, Nakao K et al (1995) Antitumor activity of the new selective protein kinase C inhibitor 4\u2019-N-benzoyl staurosporine on murine and human tumor models. Arzneimittelforschung 45(11):1225\u20131230","journal-title":"Arzneimittelforschung"},{"issue":"1","key":"10_CR30","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/nbt1358","volume":"26","author":"MW Karaman","year":"2008","unstructured":"Karaman MW, Herrgard S, Treiber DK et al (2008) A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26(1):127\u2013132","journal-title":"Nat Biotechnol"},{"key":"10_CR31","doi-asserted-by":"crossref","unstructured":"Kayser S, Schlenk RF (2017) Targeting the FLT3 mutation in acute myeloid leukemia. Eur Oncol Haematol 13(2). Epub ahead of print","DOI":"10.17925\/EOH.2017.13.02.139"},{"key":"10_CR32","doi-asserted-by":"publisher","unstructured":"Kayser S, Levis MJ (2017) Advances in targeted therapy for acute myeloid leukaemia. Br J Haematol. 2017 Nov 28. https:\/\/doi.org\/10.1111\/bjh.15032 . [Epub ahead of print] Review","DOI":"10.1111\/bjh.15032"},{"issue":"13","key":"10_CR33","doi-asserted-by":"publisher","first-page":"4270","DOI":"10.1182\/blood-2003-05-1699","volume":"102","author":"HC Kluin-Nelemans","year":"2003","unstructured":"Kluin-Nelemans HC, Oldhoff JM, Van Doormaal JJ et al (2003) Cladribine therapy for systemic mastocytosis. Blood 102(13):4270\u20134276","journal-title":"Blood"},{"issue":"2","key":"10_CR34","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.jmoldx.2010.10.004","volume":"13","author":"T Kristensen","year":"2011","unstructured":"Kristensen T, Vestergaard H, M\u00f8ller MB (2011) Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay. J Mol Diagn 13(2):180\u2013188","journal-title":"J Mol Diagn"},{"key":"10_CR35","unstructured":"Larson RA et al (2017) An analysis of maintenance therapy and post-midostaurin outcomes in the international prospective randomized, placebo-controlled, double-blind trial (CALGB 10603\/RATIFY [Alliance]) for newly diagnosed acute myeloid leukemia (AML) patients with FLT3 mutations blood 2017:ASH 2017"},{"issue":"4","key":"10_CR36","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1182\/blood-2004-01-0388","volume":"104","author":"M Levis","year":"2004","unstructured":"Levis M, Pham R, Smith BD et al (2004) In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects. Blood 104(4):1145\u20131150","journal-title":"Blood"},{"issue":"10","key":"10_CR37","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.1182\/blood-2006-04-015743","volume":"108","author":"M Levis","year":"2006","unstructured":"Levis M, Brown P, Smith BD, Stine A, Pham R, Stone R et al (2006) Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. Blood 108(10):3477\u20133483","journal-title":"Blood"},{"issue":"12","key":"10_CR38","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1182\/blood.V120.21.673.673","volume":"120","author":"MJ Levis","year":"2012","unstructured":"Levis MJ, Perl AE, Dombret H et al (2012) Final results of a phase 2 open-label, monotherapy efficacy and safety study of quizartinib (AC220) in patients with FLT3-ITD positive or negative relapsed\/refractory acute myeloid leukemia after second-line chemotherapy or hematopoietic stem cell transplantation. Blood 120(12):673","journal-title":"Blood"},{"issue":"23","key":"10_CR39","doi-asserted-by":"publisher","first-page":"5727","DOI":"10.1182\/blood-2009-02-205237","volume":"113","author":"KH Lim","year":"2009","unstructured":"Lim KH, Tefferi A, Lasho TL et al (2009a) Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood 113(23):5727\u20135736","journal-title":"Blood"},{"issue":"12","key":"10_CR40","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/ajh.21561","volume":"84","author":"KH Lim","year":"2009","unstructured":"Lim KH, Pardanani A, Butterfield JH, Li CY, Tefferi A (2009b) Cytoreductive therapy in 108 adults with systemic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. Am J Hematol 84(12):790\u2013794","journal-title":"Am J Hematol"},{"issue":"6","key":"10_CR41","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1111\/j.1365-2125.2011.03911.x","volume":"71","author":"Y Liu","year":"2011","unstructured":"Liu Y, Ramirez J, Ratain MJ (2011) Inhibition of paracetamol glucuronidation by tyrosine kinase inhibitors. Br J Clin Pharmacol 71(6):917\u2013920","journal-title":"Br J Clin Pharmacol"},{"issue":"13","key":"10_CR42","doi-asserted-by":"publisher","first-page":"4263","DOI":"10.1158\/1078-0432.CCR-08-1123","volume":"15","author":"S Meshinchi","year":"2009","unstructured":"Meshinchi S, Appelbaum FR (2009) Structural and functional alterations of FLT3 in acute myeloid leukemia. Clin Cancer Res 15(13):4263\u20134269","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10_CR43","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1093\/annonc\/mdh052","volume":"15","author":"C Monnerat","year":"2004","unstructured":"Monnerat C, Henriksson R, Le Chevalier T et al (2004) Phase I study of PKC412 (N-benzoyl- staurosporine), a novel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancer. Ann Oncol 15(2):316\u2013323","journal-title":"Ann Oncol"},{"issue":"12","key":"10_CR44","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1007\/s00277-017-3150-3","volume":"96","author":"G Nagel","year":"2017","unstructured":"Nagel G, Weber D, Fromm E et al (2017) German-Austrian AML Study Group (AMLSG). Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO). Ann Hematol 96(12):1993\u20132003","journal-title":"Ann Hematol"},{"issue":"23","key":"10_CR45","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L et al (2016) Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med 374(23):2209\u20132221 2016 Jun 9","journal-title":"N Engl J Med"},{"issue":"2","key":"10_CR46","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0145-2126(03)00185-1","volume":"28","author":"A Pardanani","year":"2004","unstructured":"Pardanani A, Hoffbrand AV, Butterfield JH, Tefferi A (2004) Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine. Leuk Res 28(2):127\u2013131","journal-title":"Leuk Res"},{"issue":"5","key":"10_CR47","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1200\/JCO.2001.19.5.1485","volume":"19","author":"DJ Propper","year":"2001","unstructured":"Propper DJ, McDonald AC, Man A, Thavasu P, Balkwill F, Braybrooke JP et al (2001) Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J Clin Oncol 19(5):1485\u20131492","journal-title":"J Clin Oncol"},{"issue":"7","key":"10_CR48","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1002\/cncr.22187","volume":"107","author":"A Quintas-Cardama","year":"2006","unstructured":"Quintas-Cardama A, Aribi A, Cortes J et al (2006) Novel approaches in the treatment of systemic mastocytosis. Cancer 107(7):1429\u20131439","journal-title":"Cancer"},{"issue":"9","key":"10_CR49","first-page":"1641","volume":"6","author":"O Rosnet","year":"1991","unstructured":"Rosnet O, Marchetto S, deLapeyriere O et al (1991) Murine Flt3, a gene encoding a novel tyrosine kinase receptor of the PDGFR\/CSF1R family. Oncogene 6(9):1641\u20131650","journal-title":"Oncogene"},{"issue":"12","key":"10_CR50","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.1182\/blood-2010-01-266742","volume":"117","author":"T Sato","year":"2011","unstructured":"Sato T, Yang X, Knapper S et al (2011) FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo. Blood 117(12):3286\u20133293","journal-title":"Blood"},{"key":"10_CR51","doi-asserted-by":"crossref","unstructured":"Schlenk RF, Fiedler W, Salih H et al (2016) Impact of age and midostaurin-dose on response and outcome in acute myeloid leukemia with FLT3-ITD: interim-analyses of the AMLSG 16-10 Trial (NCT01477606). Blood 128(22):449 (abstract)","DOI":"10.1182\/blood.V128.22.449.449"},{"issue":"6","key":"10_CR52","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1111\/all.12842","volume":"71","author":"F Siebenhaar","year":"2016","unstructured":"Siebenhaar F, Von Tschirnhaus E, Hartmann K et al (2016) Development and validation of the mastocytosis quality of life questionnaire: MCQoL. Allergy 71(6):869\u2013877","journal-title":"Allergy"},{"issue":"1","key":"10_CR53","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1182\/blood-2004-03-0891","volume":"105","author":"RM Stone","year":"2005","unstructured":"Stone RM, DeAngelo DJ, Klimek V et al (2005) Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 105(1):54\u201360","journal-title":"Blood"},{"issue":"9","key":"10_CR54","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1038\/leu.2012.115","volume":"26","author":"RM Stone","year":"2012","unstructured":"Stone RM, Fischer T, Paquette R et al (2012) Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia. Leukemia 26(9):2061\u20132068","journal-title":"Leukemia"},{"issue":"5","key":"10_CR55","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMoa1614359","volume":"377","author":"RM Stone","year":"2017","unstructured":"Stone RM, Mandrekar SJ, Sanford BL et al (2017a) Midostaurin plus chemotherapy for acute myeloid leukemia with FLT3 mutation. N Engl J Med 377(5):454\u2013464","journal-title":"N Engl J Med"},{"key":"10_CR56","unstructured":"Stone RM et al (2017b) The addition of midostaurin to standard chemotherapy decreases cumulative incidence of relapse (CIR) in the international prospective randomized, placebo-controlled, double-blind trial (CALGB 10603\/RATIFY [Alliance]) for newly diagnosed acute myeloid leukemia (AML) patients with FLT3 mutations. Blood 2017:ASH 2017"},{"issue":"4","key":"10_CR57","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1056\/NEJM200101253440415","volume":"344","author":"A Tefferi","year":"2001","unstructured":"Tefferi A, Li C-Y, Butterfield JH, Hoagland HC (2001) Treatment of systemic mastcell disease with cladribine. N Engl J Med 344(4):307\u2013309","journal-title":"N Engl J Med"},{"issue":"4","key":"10_CR58","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s00280-010-1372-3","volume":"67","author":"AW Tolcher","year":"2011","unstructured":"Tolcher AW, Appleman LJ, Shapiro GI et al (2011) A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer. Cancer Chemother Pharmacol 67(4):751\u2013764","journal-title":"Cancer Chemother Pharmacol"},{"key":"10_CR59","doi-asserted-by":"crossref","unstructured":"Utz I, Hofer S, Regenass U et al (1994) The protein kinase C inhibitor CGP 41251, a staurosporine derivative with antitumor activity, reverses multidrug resistance. Int J Cancer 57(1):104\u2013110","DOI":"10.1002\/ijc.2910570119"},{"key":"10_CR60","doi-asserted-by":"crossref","unstructured":"Valent P, Akin C, Hartmann K, Nilsson G, Reiter A, Hermine O et al (2017) Advances in the classification and treatment of mastocytosis: current status and outlook toward the future. Cancer Res 77(6):1261\u20131270","DOI":"10.1158\/0008-5472.CAN-16-2234"},{"issue":"11","key":"10_CR61","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1111\/all.12920","volume":"71","author":"B Anrooij Van","year":"2016","unstructured":"Van Anrooij B, Kluin-Nelemans JC, Safy M et al (2016) Patient-reported disease-specific quality-of-life and symptom severity in systemic mastocytosis. Allergy 71(11):1585\u20131593","journal-title":"Allergy"},{"issue":"15","key":"10_CR62","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/S1535-6108(02)00069-7","volume":"1","author":"E Weisberg","year":"2002","unstructured":"Weisberg E, Boulton C, Kelly LM et al (2002) Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell 1(15):433\u2013443","journal-title":"Cancer Cell"},{"issue":"2","key":"10_CR63","first-page":"732","volume":"61","author":"K Zaugg","year":"2001","unstructured":"Zaugg K, Rocha S, Resch H et al (2001) Differential p53-dependent mechanism of radiosensitization in vitro and in vivo by the protein kinase C-specific inhibitor PKC412. Cancer Res 61(2):732\u2013738","journal-title":"Cancer Res"}],"container-title":["Recent Results in Cancer Research","Small Molecules in Hematology"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-319-91439-8_10","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T18:20:54Z","timestamp":1571682054000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-319-91439-8_10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"ISBN":["9783319914381","9783319914398"],"references-count":64,"URL":"https:\/\/doi.org\/10.1007\/978-3-319-91439-8_10","relation":{},"ISSN":["0080-0015","2197-6767"],"issn-type":[{"value":"0080-0015","type":"print"},{"value":"2197-6767","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}